For several years, it has been clear that the de velopment of a 99 mTc-labeled tracer that is retained in the brain in proportion to local cerebral blood flow (rCBF) would be of considerable medical in terest, since it would allow CBP imaging to become a routine clinical procedure using single photon emission tomography (SPECT). Several laborato ries have devoted resources and chemical ingenuity to achieve this aim. The development of a "chem ical microsphere" class of blood flow imaging agents was spurred by the advent of iodine-123-labeled amines pioneered by the work of Winchell and co-workers with iodoisopropylam phetamine (IMP) (Winchell et aI., 1980) and by Kung and co-workers with hydroxyisopropyldi amine (H IPDM) (Kung and Blau, 1980) . 99 mTc has better imaging and dosimetry charac teristics than iodine-123. However, the basic prob lem with 99 mTc is how to incorporate the radionu elide into an organic molecule so that a lipophilic complex is formed that rapidly crosses the blood brain barrier (BBB) and is retained in the brain.
Most work has centered on derivatives of propylene amine oxime (PnAO or simply PAO) proposed by Troutner et al. (1983) and on the diaminodithiols (DADT, also called BAT for bisaminoethanethiol)
proposed independently by Kung et al. (1983) and Ravert et al. (1983) . These initial efforts were suc cessful in that rapid uptake into the brain was dem onstrated with some but not all of these lipophilic compounds. A major problem with the "first gen eration" 99 mTc brain imaging compounds was that some of them demonstrated either a high degree of plasma protein binding and did not appreciably cross the BBB or, if they did cross the BBB, they
were not retained due to rapid back-diffusion (brain to blood). Two years later and after extensive re search with more than 100 PnAO derivatives, Neir inckx and collaborators succeeded in finding a hex amethyl derivative of propylene amine oxime S1 (H M-PAO) with prolonged retention in the brain (N owotnik et aI., 1985) as well as appreciable ex traction across the BBB (Lassen et aI., 1987) . Of the diastereoisomers of HM-PAO (d,l and meso), the d,l mixture was shown to have a higher brain re tention than the meso isomer (Sharp et al., 1986) , [ 99 mTc]-d,I-HM-PAO is chemically unstable in the body and readily converts from its highly li pophilic primary form to secondary hydrophilic species (Neirinckx et aI., 1987) . This conversion takes place rapidly in cells and in various organs of the body; it occurs at a somewhat slower rate in body fluids such as plasma. The rapid intracellular conversion to hydrophilic species that do not dif fuse across cell membranes readily is thought to explain the retention of HM-PAO in the brain and other organs. The tracer has also been used clini cally to label white blood cells (mainly granulo cytes) by what may be the same conversion process (Peters et aI., 1986) .
In September of 1987, a small Symposium was patient management is briefly discussed in some of these papers. However, the preliminary nature of these results and the fact that the authors were re quested by the coeditors to be brief must be taken into account when reading these short communica tions.
We are at a point of transition in nuclear medicine and SPECT following the successful development of a 99 mTc-Iabeled compound for imaging rCBF. ). An initial report suggests that this molecule is also retained in the brain because of its intrace rebral conversion to a hydrophilic form (Walovitch et aI., 1988) . Another class of neutral 99 mTc com plexes that are boron adducts of technetium diox imes (BATOs) are being tested; at least one com pound of this series has shown promising results (Narra et aI., 1988 
